Companion diagnostic for CDK4 inhibitors

US9889135B2 · kind B2 · utility

Assignee

• Memorial Sloan Kettering Cancer Center · US

Inventors

• Andrew Koff · Seattle, US
• Aimee Crago · New York, US
• David Liu · Palo Alto, US
• Marta Kovatcheva · New York, US
• Samuel Singer · Indiana, US
• Gary K. Schwartz · New York, US
• Mark Dickson · Hollister, US
• Mary Elizabeth Klein · New York, US

Key dates

• Filing date: Oct 15, 2015
• Grant date: Feb 13, 2018
• Expiry date: Oct 15, 2035

Classification

• Technology area (CPC G): Physics
• CPC primary: G01N2800/52
• WIPO field: Measurement
• WIPO sector: Instruments

Abstract

The present invention relates to the use of one or more biomarkers to evaluate the likelihood that a CDK4 inhibitor would produce an anti-cancer effect in a subject. It is based, at least in part, on the discovery that cancer treatment with a CDK4 inhibitor is more effective where treated cancer cells undergo cellular senescence rather than a transient cell cycle arrest, where cellular senescence is associated with decreased MDM2 protein level. Accordingly, in non-limiting embodiments, the present invention provides for methods, compositions, and kits for a companion diagnostic for CDK4 inhibitors, and in particular, to the use of MDM2 expression as a biomarker for the likelihood that a cancer can be successfully treated by CDK4 inhibition.